Madison, Wisconsin 53792

  • Lymphoma


Phase I trial to study the effectiveness of topotecan and radiation therapy in treating patients who have solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells.

Study summary:

OBJECTIVES: I. Define the maximum tolerated dose and safety profile of topotecan (TOPO) administered with daily high-dose thoracic radiotherapy to a total of 60 Gy in patients with solid tumor or lymphoma. II. Assess the qualitative and quantitative nature of the toxic effects encountered in this treatment. III. Estimate the tissue and tumor TOPO concentrations during radiotherapy by evaluating plasma TOPO levels. IV. Evaluate, using Western blot and immunohistochemical stain, the effects of TOPO/radiotherapy on topoisomerase I levels in peripheral blood lymphocytes (PBL). V. Determine whether TOPO induces apoptosis in PBL from this patient population. VI. Examine tumor tissue pre- and post-treatment (if available) for topoisomerase I levels, DNA damage, topoisomerase I/DNA complexes, and apoptotic events. OUTLINE: Radiosensitization plus Radiotherapy. Topotecan, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).


DISEASE CHARACTERISTICS: - Microscopically confirmed solid tumor or lymphoma not potentially curable by conventional surgery or radiotherapy - Previously unirradiated disease scheduled to receive thoracic irradiation of up to 60 Gy, including pulmonary and esophageal tumors - No metastatic disease more effectively treated by systemic chemotherapy - No history of brain metastases PATIENT CHARACTERISTICS: - Age: 18 and over - Performance status: ECOG 0 or 1 - WBC at least 4,000 - ANC at least 1,500 - Platelets at least 100,000 - Bilirubin no greater than 1.5 mg/dL - Creatinine no greater than 1.5 mg/dL - Calcium no greater than 11.0 mg/dL - No pregnant or nursing women - Pregnancy test required, as appropriate - Effective contraception required of fertile patient PRIOR CONCURRENT THERAPY: - At least 4 weeks since chemotherapy (6 weeks since nitrosoureas and mitomycin) and recovered - At least 4 weeks since radiotherapy and recovered



Primary Contact:

Study Chair
George Wilding, MD
University of Wisconsin, Madison

Backup Contact:


Location Contact:

Madison, Wisconsin 53792
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.